Exelixis Inc Receivables, Net, Current
Exelixis Inc (EXEL) had Receivables, Net, Current of $322.21 million as of 2026-07-03, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-08-05
- 2026-07-03: Receivables, Net, Current $322.21M.
- 2026-04-03: Receivables, Net, Current $328.95M.
- 2026-01-02: Receivables, Net, Current $286.92M.
- 2025-10-03: Receivables, Net, Current $309.73M.
| Period end | Receivables, Net, Current | Receivables, Net, Current as first filed |
|---|---|---|
| 2026-07-03 | $322.21M 10-Q · filed 2026-08-05 | |
| 2026-04-03 | $328.95M 10-Q · filed 2026-05-05 | |
| 2026-01-02 | $286.92M 10-Q · filed 2026-08-05 | |
| 2025-10-03 | $309.73M 10-Q · filed 2025-11-04 | |
| 2025-07-04 | $292.35M 10-Q · filed 2025-07-28 | |
| 2025-04-04 | $281.64M 10-Q · filed 2025-05-13 | |
| 2025-01-03 | $265.44M 10-K · filed 2026-02-10 | |
| 2024-09-27 | $269.71M 10-Q · filed 2024-10-29 | |
| 2024-06-28 | $396.58M 10-Q · filed 2024-08-06 | |
| 2024-03-29 | $240.58M 10-Q · filed 2024-04-30 | |
| 2023-12-29 | $237.41M 10-K · filed 2025-02-11 | |
| 2023-09-29 | $248.11M 10-Q · filed 2023-11-01 | |
| 2023-06-30 | $232.82M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $233.92M 10-Q · filed 2023-05-09 | |
| 2022-12-30 | $214.78M 10-K · filed 2024-02-06 | |
| 2022-09-30 | $215.01M 10-Q · filed 2022-11-01 | |
| 2022-07-01 | $235.40M 10-Q · filed 2022-08-09 | |
| 2022-04-01 | $190.61M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $282.65M 10-K · filed 2023-02-07 | |
| 2021-10-01 | $179.49M 10-Q · filed 2021-11-02 | |
| 2021-07-02 | $171.75M 10-Q · filed 2021-08-05 | |
| 2021-04-02 | $177.67M 10-Q · filed 2021-05-06 | |
| 2021-01-01 | $160.88M 10-K · filed 2022-02-18 | |
| 2020-10-02 | $166.14M 10-Q · filed 2020-11-05 | |
| 2020-07-03 | $121.08M 10-Q · filed 2020-08-06 | |
| 2020-04-03 | $137.34M 10-Q · filed 2020-05-05 | |
| 2020-01-03 | $119.07M 10-K · filed 2021-02-11 | |
| 2019-09-27 | $169.79M 10-Q · filed 2019-10-30 | |
| 2019-06-28 | $97.54M 10-Q · filed 2019-07-31 | |
| 2019-03-29 | $107.67M 10-Q · filed 2019-05-01 | |
| 2018-12-28 | $162.77M 10-K · filed 2020-02-25 | |
| 2018-09-28 | $104.63M 10-Q · filed 2018-11-01 | |
| 2018-06-29 | $167.16M 10-Q · filed 2018-08-01 | |
| 2018-03-30 | $92.00M 10-Q · filed 2018-05-02 | |
| 2017-12-30 | $11.63M 10-K · filed 2019-02-22 | $88.94M 10-Q · filed 2018-11-01 |
| 2017-12-29 | $77.30M 10-K · filed 2019-02-22 | $81.19M 10-K · filed 2018-02-26 |
| 2017-09-30 | $90.00M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $43.13M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $34.08M 10-Q · filed 2017-05-01 | |
| 2016-12-31 | $40.44M 10-Q · filed 2017-11-01 | $42.25M 10-K · filed 2017-02-27 |
| 2016-12-30 | $40.44M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $91.21M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $17.80M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $10.09M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $5.18M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $3.47M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $3.76M 10-Q · filed 2015-08-11 | |
| 2015-03-31 | $3.88M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $4.88M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $4.72M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $5.03M 10-Q · filed 2014-07-31 | |
| 2014-03-31 | $4.46M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $3.94M 10-K · filed 2015-03-02 | |
| 2013-09-30 | $5.17M 10-Q · filed 2013-10-30 | |
| 2013-06-30 | $4.21M 10-Q · filed 2013-08-06 | |
| 2013-03-31 | $3.87M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $2.75M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |